Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) and Minerva Neurosciences (NASDAQ:NERV – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.
Valuation & Earnings
This table compares Ernexa Therapeutics and Minerva Neurosciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ernexa Therapeutics | $580,000.00 | 9.81 | -$14.08 million | ($3.02) | -0.06 |
| Minerva Neurosciences | N/A | N/A | -$293.42 million | ($26.80) | -0.21 |
Analyst Recommendations
This is a summary of current recommendations and price targets for Ernexa Therapeutics and Minerva Neurosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ernexa Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Minerva Neurosciences | 1 | 1 | 0 | 0 | 1.50 |
Minerva Neurosciences has a consensus price target of $7.00, indicating a potential upside of 27.04%. Given Minerva Neurosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Ernexa Therapeutics.
Institutional and Insider Ownership
70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 1.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 10.4% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Ernexa Therapeutics has a beta of 6.79, suggesting that its stock price is 579% more volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500.
Profitability
This table compares Ernexa Therapeutics and Minerva Neurosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ernexa Therapeutics | N/A | -1,262.77% | -228.54% |
| Minerva Neurosciences | N/A | N/A | -35.62% |
Summary
Ernexa Therapeutics beats Minerva Neurosciences on 6 of the 11 factors compared between the two stocks.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
